Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Methylphenidate hydrochloride 5 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Methylphenidate hydrochloride 5 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Miconazole nitrate 50 mg buccal tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Miconazole nitrate 50 mg buccal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Methylphenidate hydrochloride 10 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Methylphenidate hydrochloride 10 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clonazepam 125 microgram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clonazepam 125 microgram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely donepezil hydrochloride 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely donepezil hydrochloride 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clonazepam 250 microgram orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clonazepam 250 microgram orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Donepezil hydrochloride 5 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Donepezil hydrochloride 5 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clonazepam 500 microgram orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clonazepam 500 microgram orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clonazepam 1 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clonazepam 1 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely iodine (as povidone iodine) 200 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely iodine (as povidone iodine) 200 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clonazepam 2 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clonazepam 2 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lansoprazole 15 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lansoprazole 15 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lansoprazole 30 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lansoprazole 30 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely methylphenidate hydrochloride 2.5 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely methylphenidate hydrochloride 2.5 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Vardenafil (as vardenafil hydrochloride) 10 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Vardenafil (as vardenafil hydrochloride) 10 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Piroxicam 10 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Piroxicam 10 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Mycophenolic acid (as mycophenolate sodium) 360 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Mycophenolic acid (as mycophenolate sodium) 360 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carglumic acid 200 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely carglumic acid 200 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lamotrigine 200 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lamotrigine 200 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lamotrigine 50 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lamotrigine 50 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely lamotrigine 5 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely lamotrigine 5 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Paracetamol 650 mg and pentazocine 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Paracetamol 650 mg and pentazocine 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Paracetamol 650 mg and pentazocine 25 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clotrimazole 100 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely clotrimazole 100 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clotrimazole 200 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely clotrimazole 200 milligram/1 each conventional release vaginal tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clemastine fumarate 670 microgram and phenylpropanolamine 25 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clemastine fumarate 670 microgram and phenylpropanolamine 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Clemastine fumarate 670 microgram and phenylpropanolamine 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely zolpidem tartrate 10 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely zolpidem tartrate 10 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely zolpidem tartrate 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely zolpidem tartrate 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely zolpidem tartrate 5 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely zolpidem tartrate 5 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Zolpidem tartrate 5 mg sublingual tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Zolpidem tartrate 5 mg sublingual tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely valproic acid 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely valproic acid 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely valproic acid (as valproate semisodium) 125 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely valproic acid (as valproate semisodium) 125 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Dextromethorphan hydrobromide 60 mg and guaifenesin 1.2 g prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Dextromethorphan hydrobromide 60 mg and guaifenesin 1.2 g prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Dextromethorphan hydrobromide 60 mg and guaifenesin 1.2 g prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Benserazide 12.5 mg and levodopa 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Benserazide 12.5 mg and levodopa 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Benserazide 12.5 mg and levodopa 50 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely dextromethorphan hydrobromide 30 milligram and guaifenesin 600 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
cefaklor, vattenfritt (som cefaklor) 250 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
cefaklor, vattenfritt (som cefaklor) 250 milligram, tuggtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin, vattenfritt (som amoxicillin) 400 milligram och klavulansyra (som kaliumklavulanat) 57 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin, vattenfritt (som amoxicillin) 400 milligram och klavulansyra (som kaliumklavulanat) 57 milligram, tuggtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin, vattenfritt (som amoxicillin) 400 milligram och klavulansyra (som kaliumklavulanat) 57 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Doxycycline anhydrous (as doxycycline) 75 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Doxycycline anhydrous (as doxycycline) 75 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 250 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 250 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 250 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin, vattenfritt (som amoxicillin) 200 milligram och klavulansyra (som kaliumklavulanat) 28,5 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |